The UK’s Joint Committee on Vaccination and Immunisation (JCVI) has put forth a significant recommendation for the introduction of a…
Read More
J&J raises FY26 outlook following positive Q2 – Pharmaceutical Technology
Johnson & Johnson (J&J) announced robust second-quarter (Q2) revenues totaling approximately $25.3 billion, marking a significant 6.6% increase year-over-year (YoY).…
Read More
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More
Brinsupri Poised to Redefine Bronchiectasis Treatment Standards Following Robust ATS 2026 Showcase
The landscape of non-cystic fibrosis bronchiectasis (NCFB) treatment is undergoing a significant transformation with the emergence of Brinsupri (brensocatib), a…
Read More
Novo Nordisk’s Wegovy Poised for Significant European Expansion Following Positive CHMP Opinions on Oral and High-Dose Injectable Formulations
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has delivered two pivotal positive opinions, paving…
Read More
CERN Researchers Identify Potential Cracks in the Standard Model Following Unprecedented Observations at the Large Hadron Collider
Recent findings from ongoing research at the Large Hadron Collider (LHC) at CERN in Geneva suggest that the scientific community…
Read More
Tirzepatide Confirmed as Best-in-Class Obesity Therapy Following Landmark SURMOUNT-MAINTAIN Trial Results
Findings from the pivotal Phase III SURMOUNT-MAINTAIN trial, presented at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye,…
Read More
Wes Streeting Resigns as UK Health Secretary Citing Loss of Faith in Labour Leadership Following Local Election Debacle
The political landscape of the United Kingdom has been significantly reshaped by the dramatic resignation of Wes Streeting, the UK…
Read More
Canada Becomes First G7 Nation to Approve Generic Semaglutide Following Novo Nordisk Patent Lapse, Paving Way for Enhanced Access and Affordability
In a landmark decision poised to significantly reshape the pharmaceutical landscape for diabetes and obesity management, Health Canada has granted…
Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic Pivot
Seven months after Danish pharmaceutical giant Novo Nordisk officially shuttered its dedicated cell therapy unit in October 2025, a significant…
Read MoreYOU MAY HAVE MISSED
